Windtree Therapeutics receives $7M offer for oncology platform

Windtree Therapeutics (WINT), a micro-cap biotech, has received a non-binding letter of intent to sell its preclinical oncology aPKCi inhibitor platform for $7 million upfront, plus potential milestone payments up to $130 million and royalties that could reach $1.5 billion. The deal, which has a 21-day closing period for the oncology portion, could provide crucial funding for Windtree, which is rapidly burning cash with a negative EBITDA of $24.12 million and a current ratio of 0.25. The agreement also includes options for the buyer to acquire Windtree’s cardiovascular assets and its manufacturing agreement with Evofem Biosciences, as the company shifts its focus to near-term revenue opportunities amid a 99.45% decline in its one-year total stock return.

Analysis

Windtree Therapeutics (NASDAQ:WINT), a micro-cap biotech with a market capitalization of $2.93 million, has announced a non-binding letter of intent to divest its preclinical oncology aPKCi inhibitor platform. The proposed transaction includes a $7 million upfront payment, potentially in cash or freely tradable stock, offering non-dilutive funding, along with up to $130 million in milestone payments and substantial long-term royalties. This deal is critical for WINT, which InvestingPro data indicates is experiencing rapid cash burn, evidenced by an EBITDA of -$24.12 million and a precarious current ratio of 0.25. The oncology portion of the transaction has a 21-day closing window. The company's CEO, Jed Latkin, stated these oncology assets are not core to Windtree's future vision, aligning with a broader strategic shift to focus on near-term revenue opportunities and reduce cash burn, especially pertinent given the stock's -99.45% one-year total return. The agreement also grants the acquirer options on Windtree’s cardiovascular drug candidates and its manufacturing agreement with Evofem Biosciences, suggesting a potential for further strategic restructuring. Recent corporate actions include efforts to secure 7.5 years of U.S. market exclusivity for its cardiac drug istaroxime, raising $250,000 via Senior Secured Promissory Notes, and regaining Nasdaq listing compliance. Despite these efforts, the company's financial situation remains challenging, though InvestingPro analysis suggests its shares are currently undervalued.

Key Decisions for Investors

• Investors should closely monitor the 21-day closing period for the $7 million upfront payment from the oncology asset sale, as this is a crucial near-term liquidity event for Windtree.
• Given the significant cash burn and historical stock performance, WINT remains a high-risk, speculative investment; future value hinges on successful execution of this divestiture, achievement of milestones, and progress with its cardiovascular programs and istaroxime.
• Consider the potential for further strategic actions, including the sale of cardiovascular assets or the manufacturing agreement, which could significantly alter the company's profile and valuation.
• Evaluate the non-dilutive nature of the upfront payment against the ongoing need for capital, highlighted by the recent $250,000 note issuance, and assess the risk of future dilutive financing if milestones are delayed or other revenue streams do not materialize promptly.